1. Erratum to Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate
- Author
-
Mansoureh, Togha, Togha, Mansoureh, Masoud, Rahmat Jirde, Kiafar, Nilavari, Hosein, Ashrafian, Soodeh, Razeghi, and Leila, Kohan
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,GABA Agents ,Original ,Migraine Disorders ,Migraine prophylaxis ,Clinical Neurology ,Propranolol ,law.invention ,Cinnarizine ,Sodium valproate ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Lost to follow-up ,Adverse effect ,Valproic Acid ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Calcium Channel Blockers ,Discontinuation ,Treatment Outcome ,Anesthesiology and Pain Medicine ,Migraine ,Tolerability ,Anesthesia ,Female ,Neurology (clinical) ,Erratum ,business ,medicine.drug - Abstract
This was a double-blind clinical trial designed to assess the efficacy and safety of the cinnarizine (CIN) in patients with migraine who were refractory to propranolol and tricyclic antidepressants in comparison with sodium valproate (SV) to investigate whether CIN could be at least as effective as SV. A total of 125 patients were treated in a treatment period of 12 weeks. All patients had at least one intake of trial medication and 2-week post baseline efficacy observation which all were included in the ITT analysis. Of the 125 subjects treated, 46 discontinued prematurely: 25 from the CIN and 21 from the SV group. The main reasons for premature discontinuation were: lost to follow up (25/46, 63.2%), insufficient response (16/46, 20%), and adverse events (5/46, 12.8%). No statistically significant inter-group differences in the number of discontinuation was observed (p > 0.05). In both groups, number of attacks, intensity, and duration of attacks significantly decreased (p
- Full Text
- View/download PDF